» Articles » PMID: 38276593

Development of Pleiotropic TrkB and 5-HT Receptor Ligands As Neuroprotective Agents

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2024 Jan 26
PMID 38276593
Authors
Affiliations
Soon will be listed here.
Abstract

One common event that is the most detrimental in neurodegenerative disorders, even though they have a complex pathogenesis, is the increased rate of neuronal death. Endogenous neurotrophins consist of the major neuroprotective factors, while brain-derived neurotrophic factor (BDNF) and its high-affinity tyrosine kinase receptor TrkB are described in a number of studies for their important neuronal effects. Normal function of this receptor is crucial for neuronal survival, differentiation, and synaptic function. However, studies have shown that besides direct activation, the TrkB receptor can be transactivated via GPCRs. It has been proven that activation of the 5-HT receptor and transactivation of the TrkB receptor have a positive influence on neuronal differentiation (total dendritic length, number of primary dendrites, and branching index). Because of that and based on the main structural characteristics of LM22A-4, a known activator of the TrkB receptor, and RS67333, a partial 5-HT receptor agonist, we have designed and synthesized a small data set of novel compounds with potential dual activities in order to not only prevent neuronal death, but also to induce neuronal differentiation in neurodegenerative disorders.

Citing Articles

Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease.

Zota I, Chanoumidou K, Gravanis A, Charalampopoulos I Front Cell Neurosci. 2024; 18:1422130.

PMID: 39285941 PMC: 11402763. DOI: 10.3389/fncel.2024.1422130.


Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease.

Forsell P, Parrado Fernandez C, Nilsson B, Sandin J, Nordvall G, Segerdahl M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204102 PMC: 11357672. DOI: 10.3390/ph17080997.

References
1.
Fenner M, Achim C, Fenner B . Expression of full-length and truncated trkB in human striatum and substantia nigra neurons: implications for Parkinson's disease. J Mol Histol. 2013; 45(3):349-61. DOI: 10.1007/s10735-013-9562-z. View

2.
Daina A, Michielin O, Zoete V . iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model. 2014; 54(12):3284-301. DOI: 10.1021/ci500467k. View

3.
Yahiaoui S, Hamidouche K, Ballandonne C, Davis A, Sopkova de Oliveira Santos J, Freret T . Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease. Eur J Med Chem. 2016; 121:283-293. DOI: 10.1016/j.ejmech.2016.05.048. View

4.
Ye X, Tai W, Zhang D . The early events of Alzheimer's disease pathology: from mitochondrial dysfunction to BDNF axonal transport deficits. Neurobiol Aging. 2012; 33(6):1122.e1-10. DOI: 10.1016/j.neurobiolaging.2011.11.004. View

5.
Lecoutey C, Hedou D, Freret T, Giannoni P, Gaven F, Since M . Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proc Natl Acad Sci U S A. 2014; 111(36):E3825-30. PMC: 4246933. DOI: 10.1073/pnas.1410315111. View